Salt Lake City – May 13, 2024
Recursion Pharmaceuticals, a leading clinical-stage TechBio company, has announced the completion of BioHive-2, the largest AI supercomputer fully owned by a pharmaceutical company. Powered by NVIDIA’s cutting-edge computing platform, BioHive-2 is set to redefine drug discovery by accelerating the development and deployment of large-scale AI models.
Ranked Among the World’s Most Powerful Supercomputers
BioHive-2, an NVIDIA DGX SuperPOD, is ranked #35 globally on the Top500 list of the world’s most powerful supercomputers (as of May 2024). This milestone marks a major leap for AI in life sciences, positioning Recursion at the forefront of computational drug discovery.
Unlocking the Next Generation of Drug Discovery
“Scaling data generation and computation is key to leveraging AI for biological challenges,”
— Ben Mabey, Chief Technology Officer, Recursion
With BioHive-2 operational, Recursion can now train larger, more generalizable foundation models across chemistry and biology—cutting down research timelines and driving a paradigm shift in drug discovery.
Phenom-1 and Phenom-Beta: AI Models for Cellular Insight
The platform supports sophisticated deep learning tools like Phenom-1, a next-gen model for analyzing biologically meaningful cellular images. A smaller version, Phenom-Beta, has been released on NVIDIA’s BioNeMo platform, allowing external researchers to access and experiment with AI-powered phenotypic modeling tools for accelerated discovery.
Parallelized AI Projects with Unmatched Speed
Thanks to the scale and speed of BioHive-2, Recursion can now conduct multiple large AI experiments simultaneously, enabling faster iteration, enhanced precision, and expanded research into complex biological systems.
Strategic Collaboration with Enamine
Recursion’s AI-driven platform has demonstrated the ability to predict protein-ligand interactions across 36 billion compounds. This capability underpinned a key partnership with Enamine, a global compound provider, to develop high-value chemical libraries optimized for drug discovery.
Industry Impact: Setting a New Standard for AI in Biopharma
“Generative AI, powered by accelerated computing, is revolutionizing drug discovery,”
— Rory Kelleher, Global Head of Life Sciences BD, NVIDIA
BioHive-2 underscores a broader industry trend toward integrating generative AI and high-performance computing to scale innovation, reduce development costs, and fast-track breakthrough therapeutics.
About Recursion Pharmaceuticals
Recursion is a clinical-stage biotechnology company pioneering the industrialization of drug discovery. By integrating AI, machine learning, and one of the largest biological and chemical datasets in the industry, Recursion is reshaping the future of medicine through automation, computation, and scale.
By
